We're developing Vipax, the world's first portable, shelf-stable, broad-spectrum antivenom for snakebites. Conventional antivenom is outdated: it's expensive, labor-intensive, works for a single species of snake, can only be administered in a hospital, must be kept cold, and has a host of negative side effects for the patient. Our first product, Vipax, elegantly solves these problems while being cheaper to produce.
10x more effective than conventional antivenom.
Our antivenom saved 100% of mice from whole snake venom.
Our antivenom is made in bacteria instead of horses = cheaper and faster to produce.
Since it's made in bacteria, there are fewer risks of negative side effects in humans.
Vipax is stable at room temperatures for portability.
International patent for antivenom composition and methods.
$250K committed to $1.2M round so far.